Define the causes, risk factors, pathophysiology, clinical manifestations, complications, and nursing care plan (using the nursing process) for peptic ulcer disease, gastro‑oesophageal reflux disease, gastritis, liver cirrhosis, intestinal obstruction, hemorrhoids, acute pancreatitis, and oesophagitis.

Comprehensive Overview of Gastrointestinal Conditions

1. PEPTIC ULCER DISEASE (PUD)

Peptic ulcer disease affects 1% of the US population with a lifetime prevalence of 5-10%, and complications occur in 10-20% of patients, with hemorrhage being the most common complication (73% of cases) and perforation the most lethal (23.5% 30-day mortality). 1, 2

Definition

Peptic ulceration results from acid-peptic damage to the gastroduodenal mucosa, causing mucosal erosion that exposes underlying tissues to digestive secretions 1.

Causes and Risk Factors

• Primary causes:

  • Helicobacter pylori infection (42% of cases) 2
  • NSAID/aspirin use (36% of cases) 2
  • Smoking and alcohol abuse 1

• High-risk factors for complications:

  • Prior peptic ulcer disease or complication (2-4 fold increased risk) 3
  • Advanced age (4% increased risk per year) 3
  • Concurrent corticosteroid or anticoagulant use 3
  • High-dose or multiple NSAIDs 3
  • Low-dose aspirin combined with NSAIDs (>10-fold increased risk) 3

Pathophysiology

The disease develops when aggressive factors (acid, pepsin, H. pylori, NSAIDs) overwhelm protective mechanisms (mucus, bicarbonate, prostaglandins, blood flow). H. pylori causes chronic inflammation and disrupts mucosal defense, while NSAIDs inhibit cyclooxygenase enzymes, reducing protective prostaglandin synthesis 1, 4.

Clinical Manifestations

• Epigastric pain (often relieved by food in duodenal ulcers, worsened by food in gastric ulcers)
• Nausea and vomiting
• Complicated presentations:
  • Hematemesis (vomiting fresh blood) or coffee-ground vomiting 5
  • Melena (black tarry stools) 5
  • Acute abdominal pain with peritoneal signs (perforation)
  • Early satiety and vomiting (obstruction)

Complications

• Hemorrhage (73%): Annual incidence 0.02-0.06%, 8.6% 30-day mortality 1
• Perforation (9%): Annual incidence 0.004-0.014%, 23.5% 30-day mortality, causes 40% of ulcer-related deaths 1
• Pyloric obstruction (3%) 2

Management by Nursing Care Plan

Assessment Phase

• Immediate evaluation parameters:

  • Vital signs: pulse >100 bpm, systolic BP <100 mmHg indicate shock 5
  • Hemoglobin level and serial monitoring (>20 g/L drop in 24 hours indicates rebleeding) 5
  • Lactate levels for tissue perfusion 1
  • Signs of peritonitis: rigid abdomen, rebound tenderness, absent bowel sounds

• Risk stratification:

  • Document Boey Score or PULP score for perforated ulcers 1
  • Assess for high-risk features: age >60, comorbidities, anticoagulation

Nursing Diagnosis

• Acute pain related to mucosal erosion
• Risk for deficient fluid volume related to hemorrhage
• Risk for infection related to perforation
• Deficient knowledge regarding disease management

Planning and Implementation

For Bleeding Ulcers:

• Resuscitation targets:

  • Maintain systolic BP >100 mmHg 1
  • Hemoglobin >70 g/L (restrictive transfusion strategy unless active cardiac disease) 1
  • Normalize lactate levels 1

• Pharmacological management:

  • High-dose PPI: omeprazole 80 mg IV bolus, then 8 mg/hour infusion for 72 hours post-endoscopy 5
  • Erythromycin 250 mg IV 30-60 minutes pre-endoscopy to clear stomach 1

• Monitoring:

  • Continuous vital signs in high-dependency unit 5
  • Serial hemoglobin every 4-6 hours initially
  • Monitor for rebleeding: fresh hematemesis, melena with hemodynamic instability 5

For Perforated Ulcers:

• NPO status immediately
• Nasogastric tube insertion for decompression
• Broad-spectrum antibiotics within 1 hour 1
• Fluid resuscitation with crystalloids
• Prepare for emergency surgery or non-operative management based on clinical stability 1

For Uncomplicated Ulcers:

• Acid suppression:

  • First-line: Vonoprazan (P-CAB) for rapid, potent acid suppression 6
  • Alternative: PPI (omeprazole 20-40 mg daily or lansoprazole 30 mg daily) for 4-8 weeks 2
  • Gastric ulcers >2 cm require 8 weeks treatment 2

• H. pylori eradication (if positive testing):

  • Standard triple therapy (if low clarithromycin resistance): PPI + amoxicillin 1000 mg + clarithromycin 500 mg, all twice daily for 14 days 1
  • Sequential therapy (if high clarithromycin resistance): PPI + amoxicillin for 5 days, then PPI + clarithromycin + metronidazole for 5 days 1
  • Second-line: Levofloxacin 500 mg + amoxicillin 1000 mg + PPI for 10 days 1
  • Eradication reduces recurrence from 50-60% to 0-2% 2

• NSAID-related ulcers:

  • Discontinue NSAID (heals 95% of ulcers, reduces recurrence from 40% to 9%) 2
  • If NSAID continuation necessary: switch to lower-risk NSAID + PPI + eradicate H. pylori 2
  • For aspirin users: continue aspirin with PPI therapy 3

Patient Education

• Medication adherence:

  • Complete full course of H. pylori eradication therapy
  • Take PPIs 30 minutes before breakfast for optimal effect
  • Avoid NSAIDs; use acetaminophen for pain instead

• Lifestyle modifications:

  • Smoking cessation (mandatory counseling and referral to cessation services)
  • Limit alcohol consumption
  • Avoid foods that trigger symptoms
  • Stress management techniques

• Warning signs requiring immediate medical attention:

  • Vomiting blood or coffee-ground material
  • Black, tarry stools
  • Severe, sudden abdominal pain
  • Dizziness or fainting

Evaluation

• Symptom resolution within 2-4 weeks
• Endoscopic healing confirmation at 4-8 weeks for gastric ulcers
• H. pylori eradication confirmation with urea breath test or stool antigen 4 weeks post-treatment 4
• No recurrence at 6-12 month follow-up
• Patient demonstrates understanding of prevention strategies

---

2. GASTROESOPHAGEAL REFLUX DISEASE (GERD)

GERD symptoms occur monthly in almost 50% of US adults and weekly in 20%, with strong evidence linking chronic GERD to esophageal adenocarcinoma, though the absolute cancer risk in any individual remains low. 7

Definition

GERD occurs when gastric contents reflux into the esophagus, causing troublesome symptoms (heartburn, regurgitation) and/or complications (esophagitis, strictures, Barrett esophagus) 7.

Causes and Risk Factors

• Lower esophageal sphincter dysfunction
• Hiatal hernia (associated with more severe GERD degrees C and D) 8
• Obesity and increased intra-abdominal pressure
• Dietary factors: fatty foods, chocolate, caffeine, alcohol
• Medications: calcium channel blockers, nitrates, anticholinergics
• Smoking
• Pregnancy

Pathophysiology

Transient lower esophageal sphincter relaxations allow gastric acid and pepsin to contact esophageal mucosa. The esophageal epithelium lacks protective mechanisms present in the stomach, leading to inflammation. Chronic exposure can cause metaplastic changes (Barrett esophagus) with malignant potential 7.

Clinical Manifestations

• Typical symptoms:

  • Heartburn (retrosternal burning)
  • Regurgitation of acidic contents
  • Dysphagia (suggests stricture or severe esophagitis)

• Atypical symptoms:

  • Chronic cough
  • Laryngitis and hoarseness
  • Asthma exacerbations
  • Chest pain (non-cardiac)
  • Dental erosions

• Presentation variations by condition:

  • With peptic ulcer: heartburn predominates 8
  • Post-gastric resection: bitter taste in mouth 8
  • With hiatal hernia: retrosternal pain 8

Complications

• Erosive esophagitis (grades A-D)
• Esophageal stricture causing dysphagia
• Barrett esophagus (intestinal metaplasia with 0.5% annual cancer risk) 7
• Esophageal adenocarcinoma (rare but increasing incidence)
• Aspiration pneumonia
• Chronic laryngitis

Management by Nursing Care Plan

Assessment Phase

• Symptom characterization:

  • Frequency, severity, duration of heartburn and regurgitation
  • Relationship to meals, position, specific foods
  • Presence of alarm features: dysphagia, odynophagia, weight loss, anemia, vomiting

• Impact assessment:

  • Sleep disturbance
  • Quality of life impairment
  • Work productivity effects

• Risk factor identification:

  • BMI calculation
  • Medication review for GERD-inducing drugs
  • Smoking and alcohol history

Nursing Diagnosis

• Acute/chronic pain related to esophageal mucosal irritation
• Impaired swallowing related to esophagitis or stricture
• Disturbed sleep pattern related to nocturnal reflux
• Risk for aspiration related to regurgitation
• Deficient knowledge regarding lifestyle modifications

Planning and Implementation

Pharmacological Management:

• First-line therapy:

  • PPI: omeprazole 20 mg or lansoprazole 30 mg once daily before breakfast for 8 weeks 9
  • For severe symptoms: twice-daily dosing

• Alternative/adjunct therapy:

  • H2-receptor antagonists (less effective than PPIs): famotidine 20 mg twice daily
  • Antacids for breakthrough symptoms
  • Prokinetic agents if delayed gastric emptying documented

• Maintenance therapy:

  • Lowest effective PPI dose for symptom control
  • On-demand therapy for mild, intermittent symptoms
  • Continuous therapy for severe esophagitis, Barrett esophagus, or complications

Lifestyle Modifications (Evidence-Based):

• Dietary changes:

  • Avoid trigger foods: fatty foods, chocolate, peppermint, caffeine, alcohol, citrus, tomatoes
  • Small, frequent meals rather than large meals
  • Avoid eating within 3 hours of bedtime
  • Maintain adequate hydration

• Positional strategies:

  • Elevate head of bed 6-8 inches (not just pillows)
  • Sleep on left side
  • Remain upright for 3 hours post-meal

• Weight management:

  • Weight loss if BMI >25 (even 5-10% reduction improves symptoms)
  • Regular exercise program

• Behavioral modifications:

  • Smoking cessation (mandatory)
  • Avoid tight-fitting clothing around abdomen
  • Stress reduction techniques

Monitoring:

• Symptom diary to track triggers and response to treatment
• Weekly assessment of symptom frequency and severity
• Monitor for alarm symptoms requiring urgent evaluation
• Assess medication adherence and side effects

Endoscopic Evaluation Indications:

• Alarm symptoms present
• Age >50 with chronic symptoms (>5 years) for Barrett screening
• Symptoms refractory to 8 weeks of PPI therapy
• Dysphagia requiring stricture evaluation
• Family history of esophageal or gastric cancer

Surgical Referral Considerations:

• Refractory symptoms despite maximal medical therapy
• Patient preference to discontinue long-term medication
• Large hiatal hernia with mechanical symptoms
• Documented severe reflux with complications

Patient Education

• Medication management:

  • Take PPIs 30-60 minutes before first meal for optimal effect
  • Do not stop PPIs abruptly if on long-term therapy
  • Understand that symptom relief may take 2-4 weeks

• Lifestyle adherence:

  • Provide written list of trigger foods to avoid
  • Demonstrate proper bed elevation technique
  • Emphasize importance of weight loss if applicable

• Long-term monitoring:

  • Patients with Barrett esophagus require surveillance endoscopy every 3-5 years
  • Report new or worsening dysphagia immediately
  • Understand that GERD is typically chronic and requires ongoing management

Evaluation

• Symptom resolution or significant improvement within 8 weeks
• Improved quality of life and sleep
• Successful lifestyle modification implementation
• Healing of esophagitis on follow-up endoscopy if performed
• No progression to complications

---

3. GASTRITIS

Gastritis represents inflammation of the gastric mucosa, most commonly caused by H. pylori infection, with atrophic gastritis and intestinal metaplasia significantly increasing gastric cancer risk. 4, 10

Definition

Gastritis is inflammation of the gastric mucosa, classified as acute or chronic, erosive or non-erosive, based on endoscopic and histological findings 10.

Causes and Risk Factors

• H. pylori infection (most common cause worldwide) 4, 10
• NSAIDs and aspirin (dose-dependent risk) 10
• Alcohol abuse (acute erosive gastritis)
• Stress (critically ill patients, burns, trauma) 10
• Autoimmune gastritis (pernicious anemia)
• Bile reflux (post-gastric surgery) 8
• Infections: CMV, HSV (immunocompromised patients)
• Chemical injury: corrosives, radiation

Pathophysiology

H. pylori colonizes gastric mucosa, triggering inflammatory cascade with neutrophil and lymphocyte infiltration. Virulent CagA-positive strains cause more severe injury 10. NSAIDs inhibit COX-1, reducing protective prostaglandins and mucus production. Chronic inflammation progresses through stages: superficial gastritis → atrophic gastritis → intestinal metaplasia → dysplasia → adenocarcinoma 4, 10.

Clinical Manifestations

• Acute gastritis:

  • Epigastric pain or discomfort
  • Nausea and vomiting
  • Loss of appetite
  • Hematemesis (erosive gastritis)

• Chronic gastritis:

  • Often asymptomatic
  • Vague dyspepsia
  • Early satiety
  • Bloating

• Atrophic gastritis:

  • Vitamin B12 deficiency (pernicious anemia)
  • Iron deficiency anemia
  • Weight loss

Complications

• Peptic ulcer disease 10
• Gastric bleeding (erosive gastritis)
• Gastric cancer (significantly higher risk with atrophic gastritis and intestinal metaplasia) 10
• Vitamin B12 deficiency and megaloblastic anemia
• Iron deficiency anemia
• MALT lymphoma (H. pylori-associated)

Management by Nursing Care Plan

Assessment Phase

• Symptom evaluation:

  • Character, location, timing of epigastric discomfort
  • Relationship to meals
  • Associated nausea, vomiting, bleeding

• Risk factor assessment:

  • NSAID/aspirin use (dose, duration, frequency)
  • Alcohol consumption pattern
  • Smoking history
  • Family history of gastric cancer

• Laboratory evaluation:

  • Complete blood count (anemia)
  • H. pylori testing: stool antigen, urea breath test, or serology
  • Vitamin B12 and folate levels if atrophic gastritis suspected
  • Serum gastrin (elevated in atrophic gastritis)

Nursing Diagnosis

• Acute/chronic pain related to gastric mucosal inflammation
• Imbalanced nutrition: less than body requirements related to anorexia
• Risk for deficient fluid volume related to vomiting or bleeding
• Deficient knowledge regarding causative factors and prevention

Planning and Implementation

Pharmacological Management:

• Acid suppression:

  • PPI: omeprazole 20 mg daily for 4-8 weeks
  • H2-receptor antagonists for mild symptoms

• H. pylori eradication (if positive):

  • Standard triple therapy for 14 days (as detailed in PUD section) 1
  • Confirm eradication 4 weeks post-treatment 4

• Cytoprotective agents:

  • Sucralfate 1 g four times daily (coats and protects mucosa)
  • Bismuth subsalicylate for symptomatic relief

• For autoimmune gastritis:

  • Vitamin B12 supplementation (intramuscular if severe deficiency)
  • Iron supplementation if deficient

Causative Factor Management:

• NSAID-induced gastritis:

  • Discontinue NSAID if possible
  • Switch to selective COX-2 inhibitor with PPI if NSAID necessary
  • Use lowest effective dose for shortest duration

• Alcohol-related gastritis:

  • Immediate alcohol cessation
  • Referral to addiction services if needed
  • Nutritional support and thiamine supplementation

• Stress gastritis prevention (ICU patients):

  • PPI or H2-blocker prophylaxis for high-risk patients
  • Enteral nutrition when feasible

Dietary Management:

• Small, frequent meals
• Avoid irritants: spicy foods, caffeine, alcohol, acidic foods
• Bland diet during acute phase
• Adequate protein and calorie intake
• Vitamin-rich foods (if atrophic gastritis)

Monitoring:

• Symptom improvement tracking
• Monitor for signs of bleeding: hematemesis, melena, orthostatic hypotension
• Serial hemoglobin if anemia present
• Weight monitoring

Endoscopic Surveillance:

• Atrophic gastritis with intestinal metaplasia: endoscopy every 1-3 years for cancer surveillance 10
• Biopsy protocol: pylorus, antrum, body, angle for H. pylori and preneoplastic changes 8

Patient Education

• Medication adherence:

  • Complete full H. pylori eradication course
  • Take PPIs before meals
  • Understand importance of eradication confirmation

• Lifestyle modifications:

  • Smoking cessation
  • Alcohol avoidance
  • Stress management
  • Avoid NSAIDs; use acetaminophen instead

• Dietary guidance:

  • Identify and avoid personal trigger foods
  • Eat slowly and chew thoroughly
  • Maintain regular meal schedule

• Long-term monitoring:

  • Patients with atrophic gastritis require regular surveillance
  • Report new symptoms: persistent vomiting, weight loss, dysphagia
  • Annual B12 level monitoring if atrophic gastritis

Evaluation

• Symptom resolution within 4-8 weeks
• H. pylori eradication confirmed
• Hemoglobin normalization if anemic
• Endoscopic healing if severe gastritis
• No progression to complications
• Patient demonstrates understanding of prevention strategies

---

4. LIVER CIRRHOSIS

Liver cirrhosis represents end-stage chronic liver disease with extensive fibrosis and nodular regeneration, requiring comprehensive management to prevent life-threatening complications including variceal hemorrhage, hepatic encephalopathy, and hepatorenal syndrome.

Definition

Cirrhosis is the irreversible end-stage of chronic liver disease characterized by diffuse hepatic fibrosis, nodular regeneration, and distortion of hepatic architecture, leading to portal hypertension and hepatocellular dysfunction.

Causes and Risk Factors

• Chronic viral hepatitis: Hepatitis B and C
• Alcohol abuse (most common in Western countries)
• Non-alcoholic steatohepatitis (NASH) (increasing prevalence with obesity epidemic)
• Autoimmune hepatitis
• Primary biliary cholangitis
• Primary sclerosing cholangitis
• Hemochromatosis (iron overload)
• Wilson disease (copper accumulation)
• Alpha-1 antitrypsin deficiency
• Chronic biliary obstruction
• Cardiac cirrhosis (chronic right heart failure)
• Medications and toxins

Pathophysiology

Chronic liver injury triggers inflammatory response and stellate cell activation, producing excessive collagen and extracellular matrix. Progressive fibrosis distorts hepatic architecture, creating regenerative nodules surrounded by fibrous bands. This disrupts normal blood flow, causing portal hypertension. Portosystemic shunting and decreased hepatic synthesis lead to complications: varices, ascites, encephalopathy, coagulopathy, and hepatorenal syndrome.

Clinical Manifestations

Compensated Cirrhosis (Often Asymptomatic):

• Fatigue and weakness
• Anorexia and weight loss
• Spider angiomata
• Palmar erythema
• Mild hepatomegaly or splenomegaly

Decompensated Cirrhosis:

• Portal hypertension manifestations:

  • Ascites (abdominal distension)
  • Peripheral edema
  • Splenomegaly
  • Caput medusae (dilated abdominal wall veins)

• Hepatocellular dysfunction:

  • Jaundice (scleral icterus, dark urine)
  • Coagulopathy (easy bruising, bleeding)
  • Hypoalbuminemia (edema, ascites)

• Hepatic encephalopathy:

  • Confusion, altered mental status
  • Asterixis (flapping tremor)
  • Sleep disturbances
  • Personality changes

• Other manifestations:

  • Muscle wasting
  • Gynecomastia and testicular atrophy (men)
  • Amenorrhea (women)
  • Fetor hepaticus (musty breath odor)

Complications

• Variceal hemorrhage (10-30% mortality per episode)
• Ascites and spontaneous bacterial peritonitis
• Hepatic encephalopathy
• Hepatorenal syndrome (functional renal failure)
• Hepatopulmonary syndrome
• Hepatocellular carcinoma (annual incidence 1-6%)
• Coagulopathy and bleeding
• Malnutrition and sarcopenia
• Infections (increased susceptibility)

Management by Nursing Care Plan

Assessment Phase

• Severity classification:

  • Child-Pugh score (A, B, C based on bilirubin, albumin, INR, ascites, encephalopathy)
  • MELD score (Model for End-Stage Liver Disease) for transplant prioritization

• Comprehensive evaluation:

  • Vital signs (hypotension suggests variceal bleeding or sepsis)
  • Mental status (hepatic encephalopathy grade 0-4)
  • Abdominal examination: ascites, hepatosplenomegaly, tenderness
  • Skin examination: jaundice, spider angiomata, bruising
  • Peripheral edema assessment
  • Nutritional status and muscle wasting

• Laboratory monitoring:

  • Complete blood count (thrombocytopenia, anemia)
  • Comprehensive metabolic panel (hyponatremia, renal function)
  • Liver function tests (bilirubin, albumin, transaminases)
  • Coagulation studies (PT/INR)
  • Ammonia level (if encephalopathy suspected)

• Complication screening:

  • Upper endoscopy for variceal screening
  • Abdominal ultrasound with Doppler (portal vein patency, hepatocellular carcinoma)
  • Alpha-fetoprotein every 6 months (hepatocellular carcinoma surveillance)

Nursing Diagnosis

• Risk for bleeding related to coagulopathy and varices
• Excess fluid volume related to portal hypertension and hypoalbuminemia
• Acute confusion related to hepatic encephalopathy
• Imbalanced nutrition: less than body requirements related to anorexia and malabsorption
• Risk for infection related to immunocompromise
• Impaired skin integrity related to edema and pruritus
• Ineffective breathing pattern related to ascites
• Deficient knowledge regarding disease management and complications

Planning and Implementation

Treat Underlying Cause:

• Alcohol cessation (mandatory, refer to addiction services)
• Antiviral therapy for hepatitis B or C
• Immunosuppression for autoimmune hepatitis
• Phlebotomy for hemochromatosis
• Chelation therapy for Wilson disease

Portal Hypertension Management:

• Non-selective beta-blockers (primary prophylaxis for varices):

  • Propranolol 20-40 mg twice daily or nadolol 40-80 mg daily
  • Titrate to reduce resting heart rate by 25% or to 55-60 bpm
  • Contraindications: asthma, severe bradycardia, hypotension

• Variceal bleeding prevention:

  • Endoscopic variceal ligation for medium/large varices
  • Avoid NSAIDs and anticoagulants
  • Maintain platelet count >50,000/μL if possible

Ascites Management:

• Dietary sodium restriction: <2 grams/day (strict adherence essential)

• Diuretics:

  • Spironolactone 100 mg daily (first-line)
  • Add furosemide 40 mg daily if inadequate response
  • Titrate to achieve 0.5-1 kg weight loss daily
  • Monitor electrolytes (hyponatremia, hypokalemia) and renal function

• Large-volume paracentesis:

  • For tense ascites causing respiratory compromise
  • Albumin infusion (6-8 g per liter removed if >5 L) to prevent circulatory dysfunction
  • Strict aseptic technique

• Refractory ascites:

  • Serial large-volume paracentesis
  • Consider transjugular intrahepatic portosystemic shunt (TIPS)

• Spontaneous bacterial peritonitis (SBP) prevention:

  • Norfloxacin 400 mg daily or ciprofloxacin 750 mg weekly for high-risk patients
  • Diagnostic paracentesis if fever, abdominal pain, or encephalopathy develops

Hepatic Encephalopathy Management:

• Lactulose:

  • 15-30 mL orally 2-4 times daily
  • Titrate to 2-3 soft bowel movements daily
  • Mechanism: reduces ammonia absorption

• Rifaximin:

  • 550 mg twice daily (adjunct to lactulose)
  • Reduces ammonia-producing gut bacteria

• Precipitant identification and treatment:

  • Infection (treat with antibiotics)
  • GI bleeding (control bleeding, clear blood from gut)
  • Constipation (increase lactulose)
  • Dehydration (cautious fluid repletion)
  • Medications (discontinue sedatives, opioids)
  • Electrolyte imbalances (correct hypokalemia, hyponatremia)

• Protein restriction is NOT recommended (worsens malnutrition)

Nutritional Support:

• High-protein diet: 1.2-1.5 g/kg/day (unless acute encephalopathy)
• Frequent small meals (5-6 per day including late-evening snack)
• Branched-chain amino acid supplementation if protein-intolerant
• Multivitamin supplementation (thiamine, folate, vitamin K)
• Zinc supplementation (improves encephalopathy)
• Avoid fasting (increases muscle catabolism)

Infection Prevention:

• Vaccinations:

  • Hepatitis A and B (if not immune)
  • Pneumococcal vaccine
  • Annual influenza vaccine

• Antibiotic prophylaxis:

  • SBP prophylaxis (as above)
  • Short-term prophylaxis during GI bleeding

• Prompt treatment of infections (lower threshold for antibiotics)

Bleeding Prevention:

• Avoid NSAIDs, aspirin, anticoagulants when possible
• Vitamin K supplementation if INR elevated
• Platelet transfusion only for active bleeding or procedures (not prophylactic)
• Fresh frozen plasma only for active bleeding (not to "correct" INR)
• Use electric razor, soft toothbrush

Monitoring:

• Daily:

  • Weight (same time, same scale, after voiding)
  • Abdominal girth
  • Intake and output
  • Mental status assessment
  • Vital signs

• Regular laboratory monitoring:

  • Electrolytes, BUN, creatinine (weekly initially, then monthly)
  • Liver function tests monthly
  • Complete blood count monthly

• Surveillance:

  • Abdominal ultrasound and alpha-fetoprotein every 6 months (hepatocellular carcinoma screening)
  • Upper endoscopy every 1-3 years (variceal surveillance)

Liver Transplant Evaluation:

• Refer when MELD score ≥15 or first decompensation event
• Absolute contraindications: active alcohol/substance abuse, extrahepatic malignancy, severe cardiopulmonary disease
• Maintain transplant candidacy: abstinence, compliance, nutritional optimization

Patient Education

• Alcohol abstinence:

  • Zero tolerance (even small amounts harmful)
  • Provide addiction resources and support groups
  • Involve family in abstinence support

• Medication adherence:

  • Take diuretics in morning to avoid nocturia
  • Never skip lactulose doses
  • Avoid over-the-counter NSAIDs and herbal supplements
  • Carry medication list at all times

• Dietary compliance:

  • Provide written low-sodium diet guidelines
  • Teach label reading for sodium content
  • Emphasize adequate protein intake
  • Avoid alcohol-containing foods and mouthwash

• Self-monitoring:

  • Daily weight measurement (report >2 kg gain in 1 week)
  • Recognize early encephalopathy signs (family education crucial)
  • Monitor for bleeding: black stools, vomiting blood, easy bruising

• Infection prevention:

  • Hand hygiene
  • Avoid sick contacts
  • Seek prompt medical attention for fever

• Activity:

  • Regular moderate exercise (prevents sarcopenia)
  • Avoid heavy lifting if ascites present
  • Adequate rest periods

• Emergency situations requiring immediate medical attention:

  • Vomiting blood or black stools
  • Severe abdominal pain or fever
  • Confusion or altered mental status
  • Difficulty breathing
  • Decreased urine output

Evaluation

• Stable or improved Child-Pugh/MELD score
• Controlled ascites (weight stable, no respiratory compromise)
• No episodes of hepatic encephalopathy
• No variceal bleeding
• Adequate nutritional status maintained
• No infections
• Patient demonstrates understanding and adherence to treatment plan
• Successful transplant evaluation if indicated

---

5. INTESTINAL OBSTRUCTION

Intestinal obstruction is a surgical emergency requiring prompt recognition and intervention, with mortality ranging from 2% for simple obstruction to 25% for strangulated obstruction.

Definition

Intestinal obstruction is mechanical or functional blockage of the intestinal lumen preventing normal passage of intestinal contents, classified as small bowel obstruction (SBO) or large bowel obstruction (LBO), and as partial or complete, simple or strangulated.

Causes and Risk Factors

Small Bowel Obstruction:

• Adhesions (60-75% of cases, most common after abdominal surgery)
• Hernias (15-20%): inguinal, femoral, umbilical, incisional
• Malignancy (10-15%): primary or metastatic
• Crohn's disease (strictures) 11
• Intussusception
• Volvulus
• Foreign bodies or bezoars
• Gallstone ileus

Large Bowel Obstruction:

• Colorectal cancer (60% of cases)
• Diverticular disease (strictures)
• Volvulus (sigmoid or cecal)
• Fecal impaction
• Inflammatory bowel disease (strictures)
• Hernias

Risk Factors:

• Prior abdominal surgery (adhesions)
• History of hernias
• Inflammatory bowel disease
• Malignancy
• Advanced age
• Chronic constipation

Pathophysiology

Mechanical obstruction causes proximal bowel distension with gas and fluid accumulation. Increased intraluminal pressure impairs venous return, causing bowel wall edema and further distension. Bacterial overgrowth occurs. If arterial blood flow becomes compromised (strangulation), ischemia develops, progressing to necrosis and perforation. Fluid sequestration in bowel lumen and third-spacing cause dehydration and electrolyte imbalances. Bacterial translocation and perforation lead to peritonitis and sepsis.

Clinical Manifestations

Classic Tetrad:

• Abdominal pain: Colicky, cramping (small bowel) or constant (strangulation)
• Vomiting: Early and bilious (proximal SBO) or feculent (distal SBO/LBO)
• Abdominal distension: More prominent in LBO
• Obstipation: Inability to pass gas or stool (complete obstruction)

Physical Examination:

• Inspection: Distension, visible peristalsis, surgical scars, hernias
• Auscultation: High-pitched, tinkling bowel sounds (early) or absent (late/strangulation)
• Percussion: Tympany
• Palpation:
  • Diffuse tenderness
  • Peritoneal signs (rebound, guarding, rigidity) suggest strangulation or perforation
  • Palpable mass (tumor, hernia)
  • Rectal examination: empty rectum, occult blood

Signs of Strangulation (Surgical Emergency):

• Severe, constant pain
• Fever and tachycardia
• Peritoneal signs
• Leukocytosis with left shift
• Metabolic acidosis
• Bloody stools

Complications

• Strangulation (10-15% of SBO): Bowel ischemia and necrosis
• Perforation: Peritonitis, sepsis, death
• Aspiration pneumonia (from vomiting)
• Dehydration and electrolyte imbalances: Hypokalemia, hypochloremia, metabolic alkalosis
• Acute kidney injury (prerenal from dehydration)
• Sepsis and multiorgan failure
• Short bowel syndrome (if extensive resection required)
• Recurrent obstruction (adhesions)

Management by Nursing Care Plan

Assessment Phase

• Immediate evaluation:

  • Vital signs: tachycardia, hypotension (dehydration/sepsis), fever (strangulation)
  • Pain assessment: severity, character, location
  • Abdominal examination (as above)
  • Hydration status: skin turgor, mucous membranes, urine output

• Diagnostic workup:

  • Laboratory:

    • Complete blood count (leukocytosis suggests strangulation)
    • Comprehensive metabolic panel (electrolytes, renal function)
    • Lactate (elevated in ischemia)
    • Arterial blood gas (metabolic acidosis)

  • Imaging:

    • Abdominal X-ray (supine and upright): Dilated bowel loops, air-fluid levels, absence of colonic gas
    • CT abdomen/pelvis with IV contrast (gold standard): Identifies level, cause, and complications (strangulation, perforation)
    • Transition point, bowel wall thickening, pneumatosis, portal venous gas

Nursing Diagnosis

• Acute pain related to bowel distension and ischemia
• Deficient fluid volume related to vomiting and third-spacing
• Risk for aspiration related to vomiting
• Imbalanced nutrition: less than body requirements related to NPO status
• Risk for infection related to bacterial translocation or perforation
• Anxiety related to acute illness and potential surgery

Planning and Implementation

Initial Resuscitation (All Patients):

• NPO status (nothing by mouth)

• Nasogastric tube insertion:

  • Decompress stomach
  • Prevent aspiration
  • Monitor output (guides fluid replacement)

• Aggressive IV fluid resuscitation:

  • Lactated Ringer's or normal saline
  • Initial bolus 1-2 L, then 150-250 mL/hour
  • Target urine output >0.5 mL/kg/hour

• Electrolyte replacement:

  • Potassium chloride (hypokalemia common)
  • Correct metabolic alkalosis

• Foley catheter: Monitor urine output

• Pain management: Opioids (do not delay diagnosis)

• Antiemetics: Ondansetron 4-8 mg IV

Non-Operative Management (Partial SBO, No Strangulation):

• Indications:

  • Partial obstruction
  • No peritoneal signs
  • No signs of strangulation
  • Adhesive SBO without prior radiation or malignancy

• Conservative trial (48-72 hours):

  • NPO with NG decompression
  • IV fluids and electrolyte replacement
  • Serial abdominal examinations (every 4-6 hours)
  • Serial laboratory monitoring
  • Water-soluble contrast study (Gastrografin) at 24 hours:
    • Therapeutic (draws fluid into lumen)
    • Diagnostic (contrast in colon by 24 hours predicts resolution)

• Success indicators:

  • Decreased NG output
  • Passage of flatus or stool
  • Decreased abdominal distension
  • Improved pain
  • Contrast reaches colon

• Failure indicators (proceed to surgery):

  • No improvement after 48-72 hours
  • Worsening symptoms
  • Development of peritoneal signs
  • Persistent fever or leukocytosis

Operative Management (Indications):

• Absolute indications (immediate surgery):

  • Peritoneal signs (strangulation or perforation)
  • Complete LBO (except sigmoid volvulus amenable to endoscopic decompression)
  • Failed conservative management
  • Irreducible hernia

• Preoperative preparation:

  • Optimize resuscitation (fluid, electrolytes)
  • Broad-spectrum antibiotics (cefoxitin or cefotetan, or ceftriaxone + metronidazole)
  • Informed consent discussion: possible bowel resection, stoma

• Surgical options:

  • Adhesiolysis
  • Hernia repair
  • Bowel resection (if ischemic or malignant)
  • Bypass or stoma (if unresectable malignancy)

Postoperative Care:

• Continue NG decompression until bowel function returns
• Gradual diet advancement: clear liquids → full liquids → regular diet
• Early ambulation (reduces adhesion formation)
• Incentive spirometry (prevent atelectasis)
• Pain management
• Monitor for complications: anastomotic leak, wound infection, recurrent obstruction

Monitoring:

• Continuous:

  • Vital signs every 2-4 hours
  • Abdominal examination every 4-6 hours
  • NG output (volume, character)
  • Urine output

• Laboratory:

  • Electrolytes every 12-24 hours initially
  • Complete blood count daily
  • Lactate if strangulation suspected

• Clinical deterioration indicators:

  • Worsening pain or new peritoneal signs
  • Fever or increasing leukocytosis
  • Rising lactate
  • Decreasing urine output
  • Hemodynamic instability

Patient Education

• Postoperative:

  • Gradual return to normal diet
  • Recognize early obstruction symptoms
  • Avoid heavy lifting for 6 weeks
  • Incision care and signs of infection

• Long-term:

  • Risk of recurrent obstruction (especially adhesive SBO)
  • Maintain regular bowel habits
  • High-fiber diet (unless Crohn's disease)
  • Adequate hydration

• Emergency symptoms:

  • Severe abdominal pain
  • Persistent vomiting
  • Inability to pass gas or stool
  • Fever
  • Abdominal distension

Evaluation

• Resolution of obstruction (passage of flatus/stool, decreased distension)
• Adequate hydration and electrolyte balance
• Tolerating oral intake
• Pain controlled
• No complications (strangulation, perforation, sepsis)
• Understanding of prevention and warning signs

---

6. HEMORRHOIDS

Hemorrhoids are extremely common, affecting up to 50% of adults by age 50, and are managed conservatively in most cases, with surgical intervention reserved for severe or refractory disease.

Definition

Hemorrhoids are vascular cushions in the anal canal that become pathologically enlarged, causing symptoms. Classified as internal (above dentate line, covered by mucosa) or external (below dentate line, covered by anoderm), and graded I-IV based on prolapse severity.

Causes and Risk Factors

• Chronic constipation and straining (most common)
• Prolonged sitting (especially on toilet)
• Pregnancy and childbirth (increased intra-abdominal pressure)
• Obesity
• Low-fiber diet
• Chronic diarrhea
• Heavy lifting
• Portal hypertension (cirrhosis)
• Aging (weakening of supporting tissues)
• Genetic predisposition

Pathophysiology

Hemorrhoidal cushions are normal vascular structures providing continence. Pathological hemorrhoids develop when supporting connective tissue deteriorates, allowing cushions to engorge and prolapse. Increased intra-abdominal pressure (straining, pregnancy) and venous congestion contribute. Thrombosis can occur in external hemorrhoids. Chronic bleeding leads to iron deficiency anemia.

Clinical Manifestations

Internal Hemorrhoids:

• Painless bright red rectal bleeding (most common symptom)
  • Blood on toilet paper or coating stool
  • Dripping into toilet bowl
• Prolapse (grades II-IV)
• Mucus discharge
• Pruritus ani (itching)
• Sensation of incomplete evacuation
• Pain only if thrombosed or strangulated

External Hemorrhoids:

• Perianal swelling or lump
• Pain (especially if thrombosed)
• Pruritus
• Bleeding (if ulcerated)

Grading (Internal Hemorrhoids):

• Grade I: Bulge into canal, no prolapse
• Grade II: Prolapse with straining, spontaneous reduction
• Grade III: Prolapse with straining, require manual reduction
• Grade IV: Permanently prolapsed, cannot be reduced

Thrombosed External Hemorrhoid:

• Sudden onset severe perianal pain
• Tender, tense, bluish perianal lump
• Most painful in first 48-72 hours

Complications

• Chronic bleeding: Iron deficiency anemia
• Thrombosis: Severe pain
• Strangulation: Prolapsed hemorrhoid with compromised blood supply (severe pain, necrosis)
• Infection: Perianal abscess (rare)
• Fecal incontinence: After aggressive surgical treatment

Management by Nursing Care Plan

Assessment Phase

• History:

  • Bleeding: amount, frequency, color, relationship to bowel movements
  • Pain: severity, timing, character
  • Prolapse: frequency, reducibility
  • Bowel habits: constipation, straining, diarrhea
  • Diet: fiber and fluid intake
  • Risk factors: pregnancy, obesity, occupation

• Physical examination:

  • Inspection: Prolapse, external hemorrhoids, thrombosis, skin tags, fissures
  • Digital rectal examination: Masses, tenderness, sphincter tone
  • Anoscopy: Visualize internal hemorrhoids, grade severity

• Exclude other diagnoses:

  • Colorectal cancer (especially if age >50, weight loss, change in bowel habits)
  • Inflammatory bowel disease
  • Anal fissure
  • Perianal abscess or fistula

• Laboratory:

  • Complete blood count (if chronic bleeding, check for anemia)
  • Colonoscopy if alarm features or age-appropriate screening due

Nursing Diagnosis

• Acute/chronic pain related to thrombosis or inflammation
• Risk for deficient fluid volume related to bleeding
• Impaired skin integrity related to prolapse and moisture
• Constipation related to fear of pain with defecation
• Deficient knowledge regarding prevention and management

Planning and Implementation

Conservative Management (First-Line for Grades I-II, Many Grade III):

Dietary Modifications:

• High-fiber diet: 25-35 grams daily

  • Fruits, vegetables, whole grains, legumes
  • Fiber supplements: psyllium (Metamucil) 1 tablespoon twice daily or methylcellulose
  • Gradually increase to avoid bloating

• Adequate hydration: 8-10 glasses water daily

• Avoid straining: Do not delay urge to defecate

Bowel Habit Modifications:

• Avoid prolonged sitting on toilet (<5 minutes)
• Do not strain during defecation
• Regular bowel routine: Same time daily
• Respond promptly to urge

Topical Treatments:

• Sitz baths: Warm water 10-15 minutes, 2-3 times daily and after bowel movements

  • Reduces pain and swelling
  • Promotes hygiene

• Topical anesthetics: Lidocaine 5% ointment for pain

• Topical corticosteroids: Hydrocortisone 1% cream for inflammation (limit to 1-2 weeks to avoid skin atrophy)

• Witch hazel pads: Soothing, reduces irritation

Stool Softeners:

• Docusate sodium 100 mg twice daily
• Polyethylene glycol (Miralax) 17 g daily if constipated

Pain Management:

• Acetaminophen or NSAIDs (if not contraindicated)
• Avoid opioids (cause constipation)

Office-Based Procedures (Grades I-III):

Rubber Band Ligation (Most Common):

• Indications: Grades I-III internal hemorrhoids
• Technique: Elastic band placed at base of hemorrhoid, causing ischemia and sloughing
• Success rate: 70-80%
• Complications: Pain, bleeding (1-2%), thrombosis
• Post-procedure care:
  • Expect mild discomfort 24-48 hours
  • Sitz baths
  • High-fiber diet
  • Avoid straining
  • Hemorrhoid sloughs in 7-10 days
  • Seek care if severe pain or heavy bleeding

Sclerotherapy:

• Injection of sclerosant (phenol in oil) into submucosa
• Less effective than banding
• Used for grade I hemorrhoids

Infrared Coagulation:

• Infrared light causes coagulation
• Multiple sessions often needed
• Less effective than banding

Surgical Management (Indications):

• Grade IV hemorrhoids
• Symptomatic grade III refractory to conservative/office treatments
• Strangulated hemorrhoids
• Large thrombosed external hemorrhoids (within 48-72 hours of onset)

Hemorrhoidectomy (Excisional Surgery):

• Indications: Large, symptomatic grade III-IV hemorrhoids
• Techniques: Open (Milligan-Morgan) or closed (Ferguson)
• Most effective (95% success) but most painful
• Postoperative care:
  • Significant pain (requires opioids initially)
  • Sitz baths 3-4 times daily
  • Stool softeners
  • High-fiber diet
  • Gradual return to activities (2-4 weeks)
  • Complications: Pain, bleeding, urinary retention, infection, stenosis (rare)

Stapled Hemorrhoidopexy:

• Circular stapler repositions prolapsed tissue
• Less painful than hemorrhoidectomy
• Higher recurrence rate
• Risk of rectal perforation (rare but serious)

Thrombosed External Hemorrhoid Management:

• Within 48-72 hours: Excision under local anesthesia (provides immediate relief)
• After 72 hours: Conservative management (pain improving, clot organizing)
  • Sitz baths
  • Topical anesthetics
  • Oral analgesics
  • High-fiber diet
  • Resolves in 1-2 weeks

Monitoring:

• Symptom improvement tracking
• Bowel habit normalization
• Bleeding cessation
• Hemoglobin monitoring if chronic bleeding
• Post-procedure/surgical follow-up

Patient Education

• Dietary adherence:

  • Provide written high-fiber diet guidelines
  • Emphasize gradual fiber increase
  • Adequate fluid intake essential

• Bowel habit modification:

  • Respond promptly to urge
  • Avoid straining and prolonged sitting
  • Regular exercise promotes regularity

• Hygiene:

  • Gentle cleansing after bowel movements
  • Pat dry, do not rub
  • Avoid harsh soaps or wipes with alcohol

• Activity:

  • Avoid prolonged sitting or standing
  • Regular exercise
  • Avoid heavy lifting

• Medication use:

  • Proper application of topical treatments
  • Limit steroid use to 1-2 weeks
  • Continue fiber supplements long-term

• When to seek care:

  • Heavy bleeding
  • Severe pain
  • Fever
  • Urinary retention (post-procedure)
  • Prolapse that cannot be reduced

• Prevention:

  • Maintain high-fiber diet and hydration
  • Avoid constipation
  • Healthy weight maintenance
  • Regular exercise

Evaluation

• Symptom resolution or significant improvement
• Normal bowel habits without straining
• No bleeding
• Adequate fiber and fluid intake
• Patient demonstrates understanding of prevention strategies
• No complications from procedures or surgery
• Improved quality of life

---

7. ACUTE PANCREATITIS

Acute pancreatitis is a potentially life-threatening inflammatory condition with mortality ranging from 1-2% in mild disease to 20-30% in severe necrotizing pancreatitis, requiring aggressive early resuscitation and supportive care.

Definition

Acute pancreatitis is acute inflammation of the pancreas characterized by abdominal pain and elevated pancreatic enzymes (lipase or amylase >3 times upper limit of normal), with or without organ dysfunction and local or systemic complications.

Causes and Risk Factors

• Gallstones (40-50% of cases, most common)
• Alcohol (30-35%, second most common)
• Hypertriglyceridemia (triglycerides >1000 mg/dL)
• Post-ERCP (endoscopic retrograde cholangiopancreatography)
• Medications: Azathioprine, 6-mercaptopurine, valproic acid, thiazides, furosemide, sulfonamides, tetracyclines
• Hypercalcemia (hyperparathyroidism)
• Trauma (blunt abdominal trauma, post-surgical)
• Infections: Mumps, coxsackievirus, CMV, HIV
• Autoimmune pancreatitis
• Pancreatic divisum (congenital anomaly)
• Pancreatic or ampullary tumors
• Scorpion sting (rare, geographic-specific)
• Idiopathic (10-20%)

Pathophysiology

Premature activation of pancreatic enzymes (trypsinogen to trypsin) within pancreatic acinar cells causes autodigestion. This triggers inflammatory cascade with cytokine release (TNF-α, IL-1, IL-6), leading to local inflammation and potential systemic inflammatory response syndrome (SIRS). Severe cases develop pancreatic necrosis, fluid collections, and multiorgan dysfunction. Third-spacing of fluids causes hypovolemia. Peripancreatic fat necrosis releases free fatty acids, binding calcium (hypocalcemia). Systemic complications include acute respiratory distress syndrome (ARDS), acute kidney injury, and cardiovascular collapse.

Clinical Manifestations

• Abdominal pain (hallmark symptom):

  • Epigastric, severe, constant
  • Radiates to back (50%)
  • Worse when supine, improved sitting forward
  • Sudden onset

• Nausea and vomiting (70-90%)

• Fever (mild in uncomplicated, high in infected necrosis)

• Tachycardia

• Abdominal distension

• Decreased or absent bowel sounds (ileus)

• Jaundice (if biliary obstruction)

Physical Examination:

• Epigastric tenderness
• Abdominal guarding (may be mild initially)
• Cullen sign: Periumbilical ecchymosis (hemorrhagic pancreatitis, rare)
• Grey Turner sign: Flank ecchymosis (hemorrhagic pancreatitis, rare)
• Decreased breath sounds (pleural effusions)

Severity Classification:

• Mild (80%): No organ failure, no local/systemic complications
• Moderately severe (10%): Transient organ failure (<48 hours) or local/systemic complications
• Severe (10%): Persistent organ failure (>48 hours), high mortality

Complications

Local:

• Acute peripancreatic fluid collections (first 4 weeks)
• Pancreatic pseudocyst (>4 weeks, encapsulated)
• Acute necrotic collection (necrosis + fluid, first 4 weeks)
• Walled-off necrosis (>4 weeks, encapsulated necrosis)
• Infected necrosis (high mortality, requires intervention)
• Pancreatic abscess
• Splenic/portal vein thrombosis
• Gastrointestinal bleeding (erosion into vessels)

Systemic:

• Organ failure:
  • Respiratory: ARDS, pleural effusions
  • Renal: Acute kidney injury
  • Cardiovascular: Shock, myocardial depression
• Metabolic: Hypocalcemia, hyperglycemia, hypertriglyceridemia
• Hematologic: DIC
• Sepsis
• Chronic pancreatitis (recurrent episodes)
• Pancreatic insufficiency (exocrine and endocrine)

Management by Nursing Care Plan

Assessment Phase

• Immediate evaluation:

  • Vital signs: tachycardia, hypotension (hypovolemia), tachypnea, fever
  • Pain assessment: severity (often 8-10/10), location, radiation
  • Hydration status: skin turgor, mucous membranes, urine output
  • Respiratory status: oxygen saturation, breath sounds
  • Abdominal examination: tenderness, distension, bowel sounds

• Diagnostic criteria (require 2 of 3):

  • Characteristic abdominal pain
  • Serum lipase or amylase >3 times upper limit of normal
  • Characteristic imaging findings (CT, MRI, ultrasound)

• Laboratory evaluation:

  • Pancreatic enzymes: Lipase (more specific than amylase)
  • Complete blood count: Leukocytosis, hemoconcentration (hematocrit >44% predicts severe disease)
  • Comprehensive metabolic panel: BUN, creatinine, glucose, calcium, liver function tests
  • Arterial blood gas: Hypoxemia, metabolic acidosis
  • Triglycerides: If >1000 mg/dL, likely causative
  • Lactate dehydrogenase, C-reactive protein: Prognostic markers

• Imaging:

  • Abdominal ultrasound: Identify gallstones (perform within 24 hours)
  • Contrast-enhanced CT: Not routine initially; perform if diagnosis uncertain, no improvement after 48-72 hours, or clinical deterioration
    • Identifies necrosis, fluid collections, complications
    • Delay until after adequate resuscitation (contrast nephropathy risk)

• Severity assessment:

  • SIRS criteria (≥2 indicates severe):
    • Temperature >38°C or <36°C
    • Heart rate >90 bpm
    • Respiratory rate >20 or PaCO2 <32 mmHg
    • WBC >12,000 or <4,000 or >10% bands
  • Organ failure (persistent >48 hours indicates severe disease)
  • Ranson criteria or APACHE II score (prognostic)

Nursing Diagnosis

• Acute pain related to pancreatic inflammation
• Deficient fluid volume related to third-spacing and vomiting
• Imbalanced nutrition: less than body requirements related to NPO status and hypermetabolism
• Impaired gas exchange related to pleural effusions or ARDS
• Risk for infection related to pancreatic necrosis
• Anxiety related to severe illness and hospitalization

Planning and Implementation

Aggressive Fluid Resuscitation (Critical, First 24 Hours):

• Goal-directed therapy:

  • Lactated Ringer's solution (preferred over normal saline)
  • Initial: 15-20 mL/kg bolus, then 3 mL/kg/hour for 24-48 hours
  • Targets:
    • Urine output >0.5 mL/kg/hour
    • Heart rate <120 bpm
    • Mean arterial pressure 65-85 mmHg
    • Hematocrit 35-44%
  • Reassess every 6 hours, adjust rate
  • Aggressive early resuscitation reduces mortality and organ failure

• Monitoring:

  • Continuous vital signs
  • Hourly urine output (Foley catheter)
  • Serial hematocrit (every 8-12 hours initially)
  • Daily weights
  • Central venous pressure if severe (ICU setting)

Pain Management:

• Opioids (do not worsen pancreatitis despite old myths):
  • Morphine or hydromorphone IV
  • Patient-controlled analgesia (PCA) for severe pain
  • Titrate to pain control (often requires high doses)
• Avoid NSAIDs (renal toxicity risk in hypovolemia)

Nutritional Support:

• NPO initially if severe nausea/vomiting or ileus
• Early enteral nutrition (within 24-48 hours if tolerated):
  • Oral diet preferred if no nausea/vomiting (low-fat, soft diet)
  • Enteral tube feeding if cannot tolerate oral (nasogastric or nasojejunal)
  • Enteral superior to parenteral: Reduces infection, organ failure, mortality
  • Start with low-fat, low-residue formula
  • Advance as tolerated
• Parenteral nutrition: Only if enteral not tolerated after 5-7 days
• Avoid prolonged fasting (increases infection risk, delays recovery)

Respiratory Support:

• Supplemental oxygen to maintain SpO2 >95%
• Incentive spirometry
• Elevate head of bed 30-45 degrees
• Early mobilization
• Mechanical ventilation if ARDS develops

Antibiotic Therapy:

• NOT indicated prophylactically (no benefit, increases resistance)
• Indications for antibiotics:
  • Infected necrosis (confirmed or highly suspected)
  • Cholangitis (biliary pancreatitis)
  • Extrapancreatic infections (pneumonia, UTI, bacteremia)
• Regimen for infected necrosis: Carbapenems (imipenem, meropenem) or fluoroquinolones + metronidazole

Management of Underlying Cause:

• Gallstone pancreatitis:

  • Cholecystectomy during same hospitalization (after clinical improvement, before discharge) to prevent recurrence
  • ERCP with sphincterotomy if cholangitis or persistent biliary obstruction (within 24-48 hours)

• Alcohol-induced:

  • Alcohol cessation counseling
  • Referral to addiction services
  • Thiamine, folate supplementation

• Hypertriglyceridemia:

  • Insulin infusion (activates lipoprotein lipase)
  • Plasmapheresis if triglycerides >1000 mg/dL despite insulin
  • Long-term: fibrates, omega-3 fatty acids, low-fat diet

Management of Complications:

• Hypocalcemia: Calcium gluconate IV if symptomatic or <7 mg/dL

• Hyperglycemia: Insulin infusion to maintain glucose 140-180 mg/dL

• Infected necrosis:

  • Antibiotics
  • Delayed intervention (>4 weeks preferred, allows walled-off necrosis formation)
  • Minimally invasive approaches: endoscopic or percutaneous drainage
  • Surgical necrosectomy if minimally invasive fails

• Pseudocyst:

  • Observation if asymptomatic and <6 cm
  • Drainage if symptomatic, infected, or enlarging: endoscopic, percutaneous, or surgical

Monitoring:

• Continuous (severe cases):

  • Vital signs, oxygen saturation
  • Urine output
  • Mental status

• Daily:

  • Physical examination
  • Weight
  • Intake and output

• Laboratory:

  • Complete blood count, comprehensive metabolic panel daily initially
  • Calcium, magnesium daily if abnormal
  • Lipase (trend, not for diagnosis)
  • C-reactive protein (peaks at 48-72 hours, predicts severity)

• Imaging:

  • Repeat CT if clinical deterioration or no improvement after 7-10 days
  • Identify necrosis, fluid collections, complications

ICU Admission Criteria:

• Persistent organ failure
• SIRS
• Hemodynamic instability
• Respiratory failure
• Altered mental status
• Need for invasive monitoring

Patient Education

• Disease understanding:

  • Explain pancreatitis cause and course
  • Emphasize importance of treating underlying cause

• Dietary modifications:

  • Low-fat diet initially (gradually liberalize)
  • Small, frequent meals
  • Avoid alcohol permanently (even if not causative)
  • Adequate hydration

• Medication adherence:

  • Pain medications as prescribed
  • Pancreatic enzyme replacement if insufficiency develops
  • Medications for underlying cause (e.g., fibrates for hypertriglyceridemia)

• Lifestyle modifications:

  • Alcohol abstinence (critical)
  • Smoking cessation
  • Weight management

• Follow-up:

  • Cholecystectomy scheduling (gallstone pancreatitis)
  • Repeat imaging if fluid collections present
  • Monitor for diabetes development (pancreatic insufficiency)

• Warning signs:

  • Recurrent severe abdominal pain
  • Fever
  • Persistent vomiting
  • Jaundice
  • Shortness of breath

Evaluation

• Pain controlled
• Adequate hydration and urine output
• Tolerating oral diet
• No organ failure
• Complications identified and managed
• Underlying cause addressed
• Patient demonstrates understanding of prevention and follow-up
• Successful transition to outpatient care

---

8. OESOPHAGITIS

Oesophagitis is inflammation of the esophageal mucosa, most commonly caused by gastroesophageal reflux (erosive esophagitis), with severity grading guiding treatment intensity and duration. 5

Definition

Oesophagitis is inflammation of the esophageal mucosa from various causes, classified by etiology (reflux, infectious, eosinophilic, medication-induced, radiation) and severity (Los Angeles classification grades A-D for reflux esophagitis).

Causes and Risk Factors

• Gastroesophageal reflux disease (GERD) (most common, 5-15% of UGIB) 5

• Infections:

  • Candida (immunocompromised, diabetes, antibiotics, inhaled corticosteroids)
  • Herpes simplex virus (immunocompromised)
  • Cytomegalovirus (severe immunosuppression)

• Eosinophilic esophagitis:

  • Allergic/immune-mediated
  • Associated with food allergies, atopy

• Medication-induced:

  • Bisphosphonates (alendronate)
  • NSAIDs
  • Potassium chloride
  • Tetracyclines, doxycycline
  • Iron supplements
  • Quinidine

• Radiation esophagitis (thoracic radiation therapy)

• Caustic ingestion (acids, alkalis)

• Crohn's disease (rare)

Pathophysiology

Reflux esophagitis: Repeated acid and pepsin exposure overwhelms esophageal defenses (saliva, mucus, bicarbonate, epithelial barrier, blood flow), causing mucosal injury, inflammation, erosions, and ulcerations. Chronic inflammation can lead to Barrett esophagus (metaplasia) 7, 8.

Infectious esophagitis: Impaired immunity allows opportunistic organisms to invade esophageal mucosa, causing ulceration and inflammation.

Eosinophilic esophagitis: Food or environmental allergens trigger eosinophil-mediated inflammation, causing mucosal edema, fibrosis, and strictures.

Medication-induced: Direct mucosal contact injury from pills lodging in esophagus, especially at anatomic narrowings (aortic arch, left atrium, lower esophageal sphincter).

Clinical Manifestations

• Dysphagia (difficulty swallowing):

  • Solids (stricture, eosinophilic esophagitis)
  • Liquids and solids (severe inflammation, motility disorder)

• Odynophagia (painful swallowing):

  • Severe in infectious and medication-induced esophagitis
  • Suggests ulceration

• Heartburn and regurgitation (reflux esophagitis)

• Chest pain (retrosternal, may mimic cardiac pain)

• Food impaction (eosinophilic esophagitis)

• Nausea and vomiting

• Hematemesis or melena (severe erosive esophagitis)

• Weight loss (chronic, severe cases)

• Oral thrush (suggests candida esophagitis)

Complications

• Esophageal stricture (dysphagia, food impaction)
• Barrett esophagus (intestinal metaplasia, cancer risk) 7, 8
• Esophageal ulceration and bleeding
• Perforation (rare, caustic injury, severe infection)
• Aspiration pneumonia
• Malnutrition and weight loss
• Esophageal adenocarcinoma (Barrett progression)

Management by Nursing Care Plan

Assessment Phase

• Symptom characterization:

  • Dysphagia: onset, progression, solids vs. liquids
  • Odynophagia: severity, timing
  • Heartburn: frequency, severity, triggers
  • Associated symptoms: weight loss, bleeding

• Risk factor identification:

  • GERD symptoms
  • Immunosuppression (HIV, transplant, chemotherapy, corticosteroids)
  • Medication review (bisphosphonates, NSAIDs)
  • Radiation therapy history
  • Allergies and atopic conditions

• Physical examination:

  • Oral cavity: thrush (candida)
  • Oropharyngeal lesions (HSV)
  • Weight and nutritional status
  • Abdominal examination

• Diagnostic evaluation:

  • Upper endoscopy (EGD): Gold standard

    • Visualize mucosa: erythema, erosions, ulcers, strictures, white plaques (candida)
    • Biopsy: histology, culture (infectious), eosinophil count
    • Los Angeles classification (reflux esophagitis):
      • Grade A: ≤5 mm mucosal breaks
      • Grade B: >5 mm breaks, not continuous between mucosal folds
      • Grade C: Continuous breaks between ≥2 mucosal folds, <75% circumference
      • Grade D: Breaks involve ≥75% circumference

  • Barium esophagram: If endoscopy contraindicated or to assess stricture

  • pH monitoring: If reflux suspected but endoscopy normal

  • Esophageal manometry: If motility disorder suspected

Nursing Diagnosis

• Impaired swallowing related to inflammation or stricture
• Acute pain related to mucosal ulceration
• Imbalanced nutrition: less than body requirements related to dysphagia
• Risk for aspiration related to dysphagia
• Deficient knowledge regarding disease management

Planning and Implementation

Reflux Esophagitis Management:

• Pharmacological therapy:

  • PPI: Omeprazole 20-40 mg or esomeprazole 40 mg once daily before breakfast
    • Grade A-B: 4-8 weeks
    • Grade C-D: 8 weeks, then maintenance therapy
  • Healing rates: 80-100% at 4-8 weeks
  • Maintenance therapy: Lowest effective PPI dose (on-demand or daily)

• Lifestyle modifications:

  • Elevate head of bed 6-8 inches
  • Avoid eating 3 hours before bedtime
  • Weight loss if overweight
  • Avoid trigger foods: fatty foods, chocolate, caffeine, alcohol, citrus, tomatoes
  • Smoking cessation
  • Small, frequent meals

• Endoscopic therapy:

  • Dilation for strictures
  • Radiofrequency ablation for Barrett esophagus with dysplasia

• Surgical therapy:

  • Fundoplication for refractory symptoms or patient preference

Infectious Esophagitis Management:

• Candida esophagitis:

  • Fluconazole 200-400 mg daily for 14-21 days (first-line)
  • Alternatives: Itraconazole solution, voriconazole, echinocandins (refractory cases)
  • Treat underlying immunosuppression if possible

• HSV esophagitis:

  • Acyclovir 400 mg five times daily or 5 mg/kg IV every 8 hours for 14-21 days
  • Alternatives: Valacyclovir, famciclovir

• CMV esophagitis:

  • Ganciclovir 5 mg/kg IV every 12 hours for 21-42 days
  • Alternative: Foscarnet (if ganciclovir-resistant)
  • Maintenance therapy if severe immunosuppression

Eosinophilic Esophagitis Management:

• Dietary therapy:

  • Elimination diet (remove common allergens: milk, eggs, wheat, soy, nuts, seafood)
  • Elemental diet (amino acid-based formula) for severe cases

• Pharmacological therapy:

  • Topical corticosteroids:
    • Fluticasone 880-1760 mcg twice daily (swallowed, not inhaled)
    • Budesonide oral viscous suspension 1-2 mg twice daily
    • Duration: 8 weeks, then taper
  • PPI: High-dose (may have anti-inflammatory effect independent of acid suppression)

• Endoscopic dilation: For strictures (higher perforation risk than reflux strictures)

Medication-Induced Esophagitis Management:

• Discontinue offending medication if possible
• PPI therapy: Omeprazole 20-40 mg daily for 4-8 weeks
• Sucralfate suspension: 1 g four times daily (coats and protects mucosa)
• Prevention:
  • Take pills with full glass of water (8 oz)
  • Remain upright 30 minutes after taking
  • Avoid bedtime dosing
  • Consider liquid formulations if available

Nutritional Support:

• Dietary modifications:

  • Soft, bland diet if severe odynophagia
  • Small, frequent meals
  • Avoid irritants: spicy, acidic, very hot or cold foods
  • Adequate protein and calories

• Enteral nutrition:

  • Nasogastric or nasojejunal tube if severe dysphagia
  • Percutaneous endoscopic gastrostomy (PEG) if prolonged (>4 weeks)

• Parenteral nutrition: If enteral not tolerated

Pain Management:

• Viscous lidocaine: 15 mL swish and swallow before meals (caution: aspiration risk)
• "Magic mouthwash": Lidocaine + antacid + diphenhydramine
• Systemic analgesics: Acetaminophen, opioids if severe (avoid NSAIDs)

Monitoring:

• Symptom improvement tracking
• Weight monitoring
• Nutritional status assessment
• Medication adherence and side effects
• Follow-up endoscopy:
  • Reflux esophagitis: If symptoms persist or alarm features
  • Infectious esophagitis: If no improvement after 7-10 days
  • Eosinophilic esophagitis: 8-12 weeks to assess response
  • Barrett esophagus: Surveillance per guidelines (every 3-5 years)

Patient Education

• Medication adherence:

  • Take PPIs 30-60 minutes before breakfast
  • Complete full course of antifungal/antiviral therapy
  • Proper administration of topical corticosteroids (swallow, do not inhale)
  • Pill-taking technique (water, upright position)

• Dietary modifications:

  • Identify and avoid trigger foods (reflux)
  • Elimination diet adherence (eosinophilic)
  • Soft diet during acute phase
  • Adequate hydration

• Lifestyle modifications:

  • Bed elevation technique
  • Avoid eating before bedtime
  • Weight loss if applicable
  • Smoking cessation
  • Stress management

• Warning signs:

  • Worsening dysphagia or food impaction
  • Hematemesis or melena
  • Severe chest pain
  • Weight loss
  • Persistent vomiting

• Long-term management:

  • Barrett esophagus requires surveillance
  • Eosinophilic esophagitis is chronic, requires ongoing management
  • Reflux esophagitis often requires maintenance therapy

Evaluation

• Symptom resolution (dysphagia, odynophagia, heartburn)
• Endoscopic healing (if repeat endoscopy performed)
• Adequate nutritional intake and stable weight
• No complications (stricture, bleeding, perforation)
• Infection eradicated (if infectious cause)
• Patient demonstrates understanding of management and prevention
• Improved quality of life

---

Common Pitfalls and Caveats Across All Conditions

Diagnostic Pitfalls:

• Do not assume all epigastric pain is benign; consider cardiac causes, especially in elderly or those with risk factors
• Do not rely solely on enzyme levels for pancreatitis severity; clinical assessment and imaging are critical
• Do not delay endoscopy in upper GI bleeding with hemodynamic instability
• Do not miss alarm features requiring urgent evaluation: weight loss, dysphagia, anemia, age >50 with new symptoms

Treatment Pitfalls:

• Do not withhold opioids for pain in pancreatitis or bowel obstruction due to outdated concerns
• Do not use prophylactic antibiotics in acute pancreatitis (increases resistance without benefit)
• Do not delay H. pylori eradication confirmation (treatment failure common)
• Do not abruptly stop PPIs in patients on long-term therapy (rebound acid hypersecretion)
• Do not restrict protein in cirrhosis or hepatic encephalopathy (worsens malnutrition)

Monitoring Pitfalls:

• Do not rely on single laboratory values; trend over time is more informative
• Do not miss early signs of decompensation in cirrhosis (subtle mental status changes, increasing ascites)
• Do not ignore persistent symptoms despite treatment (consider alternative diagnosis or complications)

Patient Education Pitfalls:

• Do not assume patients understand medical terminology; use plain language
• Do not provide verbal instructions only; written materials improve adherence
• Do not neglect to assess health literacy and cultural factors affecting care

This comprehensive overview provides evidence-based, actionable nursing care plans for each gastrointestinal condition, prioritizing patient outcomes of morbidity, mortality, and quality of life.